


**Stereochemistry abstracts**

Hiroko Nakagawa\*, Masashi Moriyama, Tomoko Umahashi, Yuichi Masuoka,  
Koh-ichi Yamada

*Tetrahedron: Asymmetry* 20 (2009) 1715



$C_{22}H_{10}S_4$

(*M*)-Bisthieno[3',2':4,5]benzo[1,2-b:4,3-b']di[1]benzothiophene


$[\alpha]_{500}^{21} = -2100$  ( $c = 0.19$ , CHCl<sub>3</sub>)

Source of chirality: X-ray crystallography

Absolute configuration: (*M*)

Kaushik Sarkar, Sovan K. Singha, Shital K. Chattopadhyay\*

*Tetrahedron: Asymmetry* 20 (2009) 1719



$C_{16}H_{24}N_2O_4$

(*R*)-*tert*-Butyl 4-(1-acetyl-1*H*-pyrrol-2-yl)-2,2-dimethyloxazolidine-3-carboxylate


$[\alpha]_D = -13$  ( $c 1.0$ , CHCl<sub>3</sub>)

Source of chirality: L-serine

Absolute configuration: (4*R*)

Kaushik Sarkar, Sovan K. Singha, Shital K. Chattopadhyay\*

*Tetrahedron: Asymmetry* 20 (2009) 1719



$C_{13}H_{20}N_2O_4$

(*R*)-*tert*-Butyl 1-(1-acetyl-1*H*-pyrrol-2-yl)-2-hydroxyethylcarbamate


$[\alpha]_D = -50$  ( $c 1.0$ , CHCl<sub>3</sub>)

Source of chirality: L-serine

Absolute configuration: (1*R*)

Kaushik Sarkar, Sovan K. Singha, Shital K. Chattopadhyay\*

*Tetrahedron: Asymmetry* 20 (2009) 1719




$C_{13}H_{18}N_2O_5$

(*R*)-2-(1-Acetyl-1*H*-pyrrol-2-yl)-2-(*tert*-butoxycarbonyl)acetic acid


$[\alpha]_D = -106$  ( $c 1.0$ , CHCl<sub>3</sub>)

Source of chirality: L-serine


Absolute configuration: (2*R*)

 $C_{17}H_{26}N_2O_4$ (R)-*tert*-Butyl 4-((1-acetyl-1*H*-pyrrol-2-yl)methyl)-2,2-dimethyloxazolidine-3-carboxylate


$[\alpha]_D = +56$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: L-aspartic acid  
Absolute configuration: (4*R*)

 $C_{14}H_{22}N_2O_4$ (R)-*tert*-Butyl 3-(1-acetyl-1*H*-pyrrol-2-yl)-1-hydroxypropan-2-ylcarbamate


$[\alpha]_D = -38$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: L-aspartic acid  
Absolute configuration: (2*R*)

 $C_{14}H_{20}N_2O_5$ (R)-3-(1-Acetyl-1*H*-pyrrol-2-yl)-2-(*tert*-butoxycarbonyl)propanoic acid


$[\alpha]_D = +16$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: L-aspartic acid  
Absolute configuration: (2*R*)

 $C_{18}H_{28}N_2O_4$ (R)-*tert*-Butyl 4-(2-(1-acetyl-1*H*-pyrrol-2-yl)ethyl)-2,2-dimethyloxazolidine-3-carboxylate


$[\alpha]_D = +18$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: L-glutamic acid  
Absolute configuration: (4*R*)




$[\alpha]_D = -62$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: L-glutamic acid  
Absolute configuration: (2*R*)




(*R*)-4-(1-Acetyl-1*H*-pyrrol-2-yl)-2-(*tert*-butoxycarbonyl)butanoic acid




$[\alpha]_D^{25} = +10.2$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: stereoselective synthesis  
Absolute configuration: (2*R*,4*R*,4*'R*,5*R*)




(*R*)-Methyl 2-hydroxy-2-((4*R*,4*'R*,5*R*)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolan)-5-yl)acetate




$[\alpha]_D^{25} = +7.2$  (*c* 1.75, CHCl<sub>3</sub>)  
Source of chirality: stereoselective synthesis  
Absolute configuration: (2*R*,4*R*,4*'R*,5*R*)



(*S*)-1-((4*R*,4*'R*,5*R*)-2,2,2',2'-Tetramethyl-4,4'-bi(1,3-dioxolan)-5-yl)ethane-1,2-diol




$[\alpha]_D^{25} = +15.8$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: stereoselective synthesis  
Absolute configuration: (2*R*,4*R*,4*'R*,5*R*)




(*R*)-Phenyl((4*R*,4*'R*,5*R*)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolan)-5-yl)methanol


$[\alpha]_D^{25} = +29.3$  (*c* 7.85, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (2*R*,4*R*,4'*R*,5*R*)

(4*R*,4'*R*,5*R*)-5-((*R*)-Hexyloxy(phenyl)methyl)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolane)


$[\alpha]_D^{25} = +26.5$  (*c* 4.1, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (2*R*,4*R*,4'*R*,5*R*)

(4*R*,4'*R*,5*R*)-5-((*R*)-Dodecyloxy(phenyl)methyl)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolane)



$[\alpha]_D^{25} = +43.9$  (*c* 1.65, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*R*)

((4*R*,5*R*)-5-((*R*)-Hexyloxy(phenyl)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol

$[\alpha]_D^{25} = +31.5$  (*c* 1.40, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*R*)


((4*R*,5*R*)-5-((*R*)-Dodecyloxy(phenyl)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol

$[\alpha]_D^{25} = +53.2$  (*c* 1.75, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4*'R*,5*R*)




(4*R*,5*S*)-4-((*R*)-Hexyloxy(phenyl)methyl)-5-(iodomethyl)-2,2-dimethyl-1,3-dioxolane

$[\alpha]_D^{25} = +33.3$  (*c* 0.90, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4*'R*,5*R*)




(4*R*,5*S*)-4-((*R*)-Dodecyloxy(phenyl)methyl)-5-(iodomethyl)-2,2-dimethyl-1,3-dioxolane

$[\alpha]_D^{25} = +28.0$  (*c* 0.25, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4*'R*,5*R*)




(1*R*,2*R*)-2-(Hexyloxy)-1-((*R*)-oxiran-2-yl)-2-phenylethanol

$[\alpha]_D^{25} = -34$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4*'R*,5*R*)




(1*R*,2*R*)-2-(Dodecyloxy)-1-((*R*)-oxiran-2-yl)-2-phenylethanol


$[\alpha]_D^{25} = +71.0$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (5*R*,6*S*,7*R*)

(5*R*,6*S*,7*R*)-Ethyl 6-(tert-butyldimethylsilyloxy)-7-(hexyloxy)-5-hydroxy-7-phenylhept-2-yneate


$[\alpha]_D^{25} = +54.10$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (5*R*,6*S*,7*R*)

(5*R*,6*S*,7*R*)-Ethyl 6-(tert-butyldimethylsilyloxy)-7-(dodecyloxy)-5-hydroxy-7-phenylhept-2-yneate


$[\alpha]_D^{25} = -0.8$  (*c* 0.50, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (5*R*,6*S*,7*R*)

(R)-6-((1*S*,2*S*)-1-Hydroxy-2-methoxy-2-phenylethyl)-5,6-dihydropyran-2-one

$[\alpha]_D^{25} = -3.5$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (5*R*,6*S*,7*R*)


(R)-6-((1*S*,2*R*)-2-(Hexyloxy)-1-hydroxy-2-phenylethyl)-5,6-dihydropyran-2-one

$[\alpha]_D^{25} = +11.6$  (*c* 0.8, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*R*)




Phenyl((4*R*,4'*R*,5*S*)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolan)-5-yl)methanone

$[\alpha]_D^{25} = +15.7$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*R*)




(S)-Phenyl((4*R*,4'*R*,5*R*)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolan)-5-yl)methanol

$[\alpha]_D^{25} = +59.6$  (*c* 0.5, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*R*)




(4*R*,4'*R*,5*R*)-5-((S)-Methoxy(phenyl)methyl)-2,2,2',2'-tetramethyl-4,4'-bi(1,3-dioxolane)

$[\alpha]_D^{25} = +55.9$  (*c* 2.1, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*S*)





((4*R*,5*R*)-5-((S)-Methoxy(phenyl)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol

$[\alpha]_D^{25} = +63.1$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*S*)





(4*S*,5*R*)-4-(iodomethyl)-5-((*S*)-methoxy(phenyl)methyl)-2,2-dimethyl-1,3-dioxolane

$[\alpha]_D^{25} = +36.9$  (*c* 2.9, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (4*R*,4'*R*,5*S*)





(1*R*,2*S*)-2-Methoxy-1-((*R*)-oxiran-2-yl)-2-phenylethanol

$[\alpha]_D^{25} = +60.5$  (*c* 1.4, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (5*R*,6*S*,7*S*)




(5*R*,6*S*,7*S*)-Ethyl 6-(tert-butyldimethylsilyloxy)-5-hydroxy-7-methoxy-7-phenylhept-2-ynoate

$[\alpha]_D^{25} = +23.4$  (*c* 0.35, CHCl<sub>3</sub>)  
 Source of chirality: stereoselective synthesis  
 Absolute configuration: (5*R*,6*S*,7*R*)



(*R*)-6-((1*S*,2*R*)-2-(Dodecyloxy)-1-hydroxy-2-phenylethyl)-5,6-dihydropyran-2-one




C<sub>14</sub>H<sub>15</sub>NO<sub>3</sub>

N-((1S,2R)-1-Hydroxy-1-phenylpropan-2-yl)furan-2-carboxamide

[ $\alpha$ ]<sub>D</sub><sup>30</sup> = +70.4 (c 0.125, CHCl<sub>3</sub>)

Source of chirality: (1S,2R)-(+)-norephedrine

Absolute configuration: (1S,2R)



C<sub>20</sub>H<sub>19</sub>NO<sub>3</sub>S


2,3,3a,4-Tetrahydro-6-phenyl-2-tosylcyclopenta[c]pyrrol-5-one

Ee = 99%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -87.0 (c 2.0, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: chiral catalyst

Absolute configuration: (3R)



C<sub>14</sub>H<sub>15</sub>NO<sub>3</sub>S


2,3,3a,4-Tetrahydro-2-tosylcyclopenta[c]pyrrol-5-one

Ee = 99%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +193.7 (c 2.5, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: chiral catalyst

Absolute configuration: (3R)



C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>



(S)-Benzyl 2-((2R,3S)-1-(benzyloxy)-3-hydroxy-1-oxobutan-2-ylcarbamoyl)pyrrolidine-1-carboxylate

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -53 (c 1, CHCl<sub>3</sub>)

Source of chirality: L-proline, L-threonine



Absolute configuration: (2R,3S)

$[\alpha]_D^{25} = -30.4$  (*c* 1.0, CHCl<sub>3</sub>)  
 Source of chirality: L-proline, L-threonine  
 Absolute configuration: (2*R*,3*S*)




(S)-Benzyl 2-((2*R*,3*S*)-1-(benzyloxy)-3-(*tert*-butyldimethylsilyloxy)-1-oxobutan-2-ylcarbamoyl)pyrrolidine-1-carboxylate

$[\alpha]_D^{25} = -21.1$  (*c* 0.5, CHCl<sub>3</sub>)  
 Source of chirality: L-proline, L-threonine  
 Absolute configuration: (2*R*,3*S*)




(2*R*,3*S*)-3-(*tert*-Butyldimethylsilyloxy)-2-(S)-pyrrolidine-2-carboxamido)butanoic acid

$[\alpha]_D^{25} = +65.9$  (*c* 1, CHCl<sub>3</sub>)  
 Source of chirality: aldol reaction  
 Absolute configuration: (R)




(R)-4-(2-Fluorophenyl)-4-hydroxybutan-2-one


ee >99%  
 $[\alpha]_D^{25} = -4031$  (*c* 0.032, MeOH)  
 Source of chirality: synthesis from (S)-valine  
 Absolute configuration:  $\Lambda$ , (S,S)




Lithium  $\Lambda$ -bis[N-salicylidene-(S)-valinato]cobaltate




ee >99%  
 $[\alpha]_D^{25} = -8631$  (c 0.032, MeOH)  
 Source of chirality: synthesis from (S)-valine  
 Absolute configuration: Δ, (S,S)




Lithium Δ-bis[N-salicylidene-(S)-valinato]cobaltate




ee >99%  
 $[\alpha]_D^{25} = -3458$  (c 0.031, MeOH)  
 Source of chirality: synthesis from (S)-valine  
 Absolute configuration: Λ, (S,S)




Lithium Λ-bis[N-(3-methoxysalicylidene)-(S)-valinato]cobaltate




ee >99%  
 $[\alpha]_D^{25} = -6982$  (c 0.034, MeOH)  
 Source of chirality: synthesis from (S)-valine  
 Absolute configuration: Δ, (S,S)




Lithium Δ-bis[N-(3-methoxysalicylidene)-(S)-valinato]cobaltate



ee >99%  
 $[\alpha]_D^{25} = -4500$  (c 0.027, MeOH)  
 Source of chirality: synthesis from (S)-tert-leucine  
 Absolute configuration: Λ, (S,S)



Lithium Λ-bis[N-(3-methoxysalicylidene)-(S)-tert-leucinato]cobaltate




ee >99%


$[\alpha]_D^{25} = -5763$  (*c* 0.027, MeOH)

Source of chirality: synthesis from (*S*)-*tert*-leucine

Absolute configuration: Δ, (*S,S*)



Lithium Δ-bis[N-(3-methoxysalicylidene)-(S)-*tert*-leucinato]cobaltate




ee >99%


$[\alpha]_D^{25} = -4633$  (*c* 0.06, MeOH)

Source of chirality: synthesis from (*S*)-valine

Absolute configuration: Λ, (*S,S*)



Lithium Λ-bis[N-(3-allylsalicylidene)-(S)-valinato]cobaltate




ee >99%


$[\alpha]_D^{25} = -732$  (*c* 0.044, MeOH)

Source of chirality: synthesis from (*S*)-valine

Absolute configuration: Δ, (*S,S*)



Lithium Δ-bis[N-(3-allylsalicylidene)-(S)-valinato]cobaltate



ee >99%


$[\alpha]_D^{25} = -3697$  (*c* 0.035, MeOH)

Source of chirality: synthesis from (*S*)-valine


Absolute configuration: Λ, (*S,S*)




Sodium Λ-bis[N-(3-methoxysalicylidene)-(S)-valinato]cobaltate




ee >99%  
 $[\alpha]_D^{25} = -8046$  (*c* 0.035, MeOH)  
 Source of chirality: synthesis from (*S*)-valine  
 Absolute configuration:  $\Delta$ , (*S,S*)




Sodium  $\Delta$ -bis[*N*-(3-methoxysalicylidene)-(S)-valinato]cobaltate




$[\alpha]_D^{20} = -198.4$  (*c* 0.64,  $\text{CH}_2\text{Cl}_2$ )  
 Source of chirality: L-proline and (*S*)-2-(2'-piperidinyl)pyridine  
 Absolute configuration: (*S*, 2*S*)




(*S*)-2-(2'-Piperidinyl)pyridine derived L-prolinamide




$[\alpha]_D^{20} = +70.0$  (*c* 1,  $\text{CH}_2\text{Cl}_2$ )  
 Source of chirality: L-proline and (*R*)-2-(2'-piperidinyl)pyridine  
 Absolute configuration: (*R*, 2*S*)





(*R*)-2-(2'-Piperidinyl)pyridine derived L-prolinamide



$[\alpha]_D^{20} = -100.0$  (*c* 0.1,  $\text{CH}_2\text{Cl}_2$ )  
 Source of chirality: *trans*-4-hydroxy-L-proline and (*S*)-2-(2'-piperidinyl)pyridine  
 Absolute configuration: (*S*, 2*S*, 4*R*)



(*S*)-2-(2'-Piperidinyl)pyridine derived *trans*-4-hydroxy-L-prolinamide





(R)-2-(2'-Piperidinyl)pyridine derived *trans*-4-hydroxy-L-prolinamide

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +61.7 (c 0.47, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: *trans*-4-hydroxy-L-proline and (R)-2-(2'-piperidinyl) pyridine

Absolute configuration: (R, 2S, 4R)




(2S,αR)-α-(2-Carbamoylpiperidinyl)-α-phenylacetic acid methyl ester

[ $\alpha$ ]<sub>D</sub> = -125.0 (c 1, CHCl<sub>3</sub>)

Source of chirality: (S)-(+)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester, (S)-(−)-2-piperidine-carboxamide

Absolute configuration: (2S,αR)




(2S,αS)-α-(2-Carbamoylpiperidinyl)-α-phenylacetic acid methyl ester

[ $\alpha$ ]<sub>D</sub> = +3.0 (c 1, CHCl<sub>3</sub>)

Source of chirality: (R)-(-)-2-(4-toluenesulfonyloxy)-phenylacetic acid methyl ester, (S)-(−)-2-piperidine-carboxamide

Absolute configuration: (2S,αS)



(4R,9aS)-4-Phenyl-perhydropyrido[1,2-a]pyrazine-1,3-dione



[ $\alpha$ ]<sub>D</sub> = -137.4 (c 1, CHCl<sub>3</sub>)

Source of chirality: (2S,αR)-α-(2-carbamoylpiperidinyl)-α-phenylacetic acid methyl ester

Absolute configuration: (4R,9aS)

Maciej Dawidowski \*, Franciszek Herold, Marcin Wilczek, Jerzy Kleps, Irena Wolska, Jadwiga Turło, Andrzej Chodkowski, Paweł Widomski, Anna Bielejewska

Tetrahedron: Asymmetry 20 (2009) 1759



(4S,9aS)-4-Phenyl-perhydropyrido[1,2-a]pyrazine-1,3-dione


$[\alpha]_D = -97.1 \text{ (c 1, CHCl}_3\text{)}$

Source of chirality: (2*S*,*αS*)-*α*-(2-carbamoylpiperidinyl)-*α*-phenylacetic acid methyl ester

Absolute configuration: (4*S*,9*aS*)

Sharad P. Panchgalle, Rohitkumar G. Gore, Subhash P. Chavan, Uttam R. Kalkote \*

Tetrahedron: Asymmetry 20 (2009) 1767



(*S*)-3-(1'-Naphthoxy)propane-1,2-diol

$Ee = 98\%$



$[\alpha]_D^{25} = +6.7 \text{ (c 1.05 MeOH)}$

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*)

Sharad P. Panchgalle, Rohitkumar G. Gore, Subhash P. Chavan, Uttam R. Kalkote \*

Tetrahedron: Asymmetry 20 (2009) 1767



(*S*)-2-((1'-Naphthoxy)-methyl)oxirane

$Ee = 98\%$



$[\alpha]_D^{25} = -34.0 \text{ (c 1.52, MeOH)}$

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*)

Sharad P. Panchgalle, Rohitkumar G. Gore, Subhash P. Chavan, Uttam R. Kalkote \*

Tetrahedron: Asymmetry 20 (2009) 1767




(*S*)-1-(Isopropylamino)-3-(1'-naphthoxy)propan-2-ol or (*S*)-propranolol

$Ee = 98\%$

$[\alpha]_D^{25} = -9.8 \text{ (c 0.55, EtOH)}$


Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*)




$C_{24}H_{28}N_2O_3$   
(*S*)-1-[4-(2'-Methoxyphenyl)-piperazin-1-yl]-3-(1'-naphthoxy)-2-propanol or (*S*)-naftopidil

Ee = 98%  
 $[\alpha]_D^{25} = +4.7$  (*c* 1.55, MeOH)  
Source of chirality: asymmetric synthesis  
Absolute configuration: (2*S*)




$C_8H_{10}N_2O_2$   
(*S*)-3-Amino-3-(3-pyridyl)propanoic acid

Ee >99% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -5.1$  (*c* 0.41, H<sub>2</sub>O)  
Source of chirality: lipase PS-catalyzed hydrolysis  
Absolute configuration: (3*S*)




$C_8H_{11}ClN_2O_2$   
(*S*)-3-Amino-3-(3-pyridyl)propanoic acid hydrochloride

Ee >99% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -3.9$  (*c* 0.33, H<sub>2</sub>O)  
Source of chirality: lipase PS-catalyzed hydrolysis  
Absolute configuration: (3*S*)




$C_7H_9NO_3$   
(*S*)-3-Amino-3-(2-furyl)propanoic acid

Ee >99% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -5.8$  (*c* 0.52, H<sub>2</sub>O)  
Source of chirality: lipase PS-catalyzed hydrolysis  
Absolute configuration: (3*S*)

 $C_7H_{10}ClNO_3$ 


(S)-3-Amino-3-(2-furyl)propanoic acid hydrochloride

Ee >99% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -4.9$  (*c* 0.32, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)

 $C_7H_9NO_3$ 


(S)-3-Amino-3-(3-furyl)propanoic acid

Ee >99% by GC on a Chirasil L-Val column after derivatization with CH<sub>2</sub>N<sub>2</sub> and (PrCO)<sub>2</sub>O  
 $[\alpha]_D^{25} = -6.7$  (*c* 0.34, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)

 $C_7H_{10}ClNO_3$ 


(S)-3-Amino-3-(3-furyl)propanoic acid hydrochloride

Ee >99% by GC on a Chirasil L-Val column after derivatization with CH<sub>2</sub>N<sub>2</sub> and (PrCO)<sub>2</sub>O  
 $[\alpha]_D^{25} = -4.6$  (*c* 0.42, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)

 $C_7H_9NO_2S$ 


(S)-3-Amino-3-(2-thienyl)propanoic acid

Ee >99% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -9.9$  (*c* 0.41, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)

 $C_7H_{10}ClNO_2S$ 


(S)-3-Amino-3-(2-thienyl)propanoic acid hydrochloride

Ee >99% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -3.1$  (*c* 0.33,  $H_2O$ )  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3*S*)

 $C_7H_9NO_2S$ 


(S)-3-Amino-3-(3-thienyl)propanoic acid

Ee >99% by GC on a Chirasil L-Val column after derivatization with  $CH_2N_2$  and  $(EtCO)_2O$   
 $[\alpha]_D^{25} = -3.2$  (*c* 0.32,  $H_2O$ )  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3*S*)

 $C_7H_{10}ClNO_2S$ 


(S)-3-Amino-3-(3-thienyl)propanoic acid hydrochloride

Ee >99% by GC on a Chirasil L-Val column after derivatization with  $CH_2N_2$  and  $(EtCO)_2O$   
 $[\alpha]_D^{25} = -3.6$  (*c* 0.34,  $H_2O$ )  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3*S*)

 $C_8H_{10}N_2O_2$ 


(S)-3-Amino-3-(2-pyridyl)propanoic acid

Ee >99% by HPLC on a Chiralpak IA column after derivatization with  $CH_2N_2$   
 $[\alpha]_D^{25} = -18.2$  (*c* 0.32,  $H_2O$ )  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3*S*)




C<sub>8</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub>  
(S)-3-Amino-3-(2-pyridyl)propanoic acid hydrochloride

Ee >99% by HPLC on a Chiralpak IA column after derivatization with CH<sub>2</sub>N<sub>2</sub>  
 $[\alpha]_D^{25} = -8.6$  (c 0.31, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)




C<sub>8</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>  
(S)-3-Amino-3-(4-pyridyl)propanoic acid

Ee = 98% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -11.7$  (c 0.36, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)




C<sub>8</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub>  
(S)-3-Amino-3-(4-pyridyl)propanoic acid hydrochloride

Ee = 98% by HPLC on a Chirobiotic TAG column  
 $[\alpha]_D^{25} = -3.6$  (c 0.35, H<sub>2</sub>O)  
 Source of chirality: lipase PS-catalyzed hydrolysis  
 Absolute configuration: (3S)




C<sub>16</sub>H<sub>19</sub>NO<sub>4</sub>  
(1aR,4aS,4bS,5R)-5-Benzoyloxy-octahydrofuro[3,4-d]pyridin[1,2-b]isoxazol-4(3H)-one

$[\alpha]_D^{25} = +57.3$  (c 1.85, CH<sub>2</sub>Cl<sub>2</sub>)  
 Source of chirality: asymmetric synthesis  
 Absolute configuration: 1aR,4aS,4bS,5R

 $C_{16}H_{19}NO_4$ 


(1aS,4aR,4bS,5R)-5-Benzyl-2-hydroxyoctahydrofuro[3,4-d]pyridin[1,2-b]isoxazol-4(3H)-one

$[\alpha]_D^{25} = +11.3$  (*c* 0.6,  $\text{CH}_2\text{Cl}_2$ )  
 Source of chirality: asymmetric synthesis  
 Absolute configuration: 1aS,4aR,4bS,5R

 $C_{17}H_{21}NO_5$ 

(1aR,2R,4aS,4bS,5R)-5-Benzyl-2-hydroxymethyl-octahydrofuro[3,4-d]pyridino[1,2-b]isoxazol-4(3H)-one


$[\alpha]_D^{25} = +2.24$  (*c* 2.24,  $\text{CH}_2\text{Cl}_2$ )  
 Source of chirality: asymmetric synthesis  
 Absolute configuration: 1aR,2R,4aS,4bS,5R


 $C_{17}H_{21}NO_5$ 

(1aS,2R,4aR,4bS,5R)-5-Benzyl-2-hydroxymethyl-octahydrofuro[3,4-d]pyridin[1,2-b]isoxazol-4(3H)-one


$[\alpha]_D^{25} = +100.3$  (*c* 0.75,  $\text{CH}_2\text{Cl}_2$ )  
 Source of chirality: asymmetric synthesis  
 Absolute configuration: 1aS,2R,4aR,4bS,5R

$[\alpha]_D^{25} = -43$  (*c* 1.5,  $\text{CHCl}_3$ )  
 Source of chirality: L-rhamnose


 $C_{27}H_{30}O_6$ 4-Methoxyphenyl 3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranoside

 $C_{42}H_{50}O_{14}$ 4-Methoxyphenyl (2,4,6-tri-O-acetyl-3-O-allyl- $\beta$ -D-galactopyranosyl)-(1→2)-3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranoside


$[\alpha]_D^{25} = +12.3$  (*c* 1.5, CHCl<sub>3</sub>)  
Source of chirality: D-galactose, L-rhamnose

 $C_{76}H_{82}O_{16}$ 4-Methoxyphenyl (2-O-acetyl-3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranosyl)-(1→3)-(2,4,6-tri-O-benzyl- $\beta$ -D-galactopyranosyl)-(1→2)-3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranoside

$[\alpha]_D^{25} = +2.6$  (*c* 1.5, CHCl<sub>3</sub>)  
Source of chirality: D-galactose, L-rhamnose


4-Methoxyphenyl (2,3-di-O-acetyl-4-O-benzyl- $\alpha$ -L-rhamnopyranosyl)-(1→2)-(3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranosyl)-(1→3)-(2,4,6-tri-O-benzyl- $\beta$ -D-galactopyranosyl)-(1→2)-3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranoside

$[\alpha]_D^{25} = -7.5$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: D-galactose, L-rhamnose





$[\alpha]_D^{25} = -2.3$  (*c* 1.0, CHCl<sub>3</sub>)  
Source of chirality: D-glucose, L-rhamnose


4-Methoxyphenyl (2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-(1→3)-[(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-(1→4)]-2-O-acetyl- $\alpha$ -L-rhamnopyranoside



4-Methoxyphenyl (2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-(1→3)-[(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-(1→4)]-2-O-acetyl- $\alpha$ -L-rhamnopyranosyl-(1→3)-(2-O-acetyl-4-O-benzyl- $\alpha$ -L-rhamnopyranosyl)-(1→2)-(3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranosyl)-(1→3)-(2,4,6-tri-O-benzyl- $\beta$ -D-galactopyranosyl)-(1→2)-3,4-di-O-benzyl- $\alpha$ -L-rhamnopyranoside




4-Methoxyphenyl (sodium  $\beta$ -D-glucopyranosyl uronate)-(1→3)-[(sodium  $\beta$ -D-glucopyranosyl uronate)-(1→4)]- $\alpha$ -L-rhamnopyranosyl-(1→3)-( $\alpha$ -L-rhamnopyranosyl)-(1→2)-( $\alpha$ -L-rhamnopyranosyl)-(1→3)-( $\beta$ -D-galactopyranosyl)-(1→2)- $\alpha$ -L-rhamnopyranoside




Dimethyl (2R,3S)-2-ethyl-3-hydroxybutanedioate

$[\alpha]_D^{25} = +9.3$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (2R,3S)




(2S,3S)-3-Ethylbutane-1,2,4-triol

$[\alpha]_D^{25} = +19.5$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (2S,3S)




[(2S,4S,5S)-5-Ethyl-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]methanol

$[\alpha]_D^{25} = +31.5$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (4S,5S)




(2S,4R,5S)-5-Ethyl-2-(4-methoxyphenyl)-4-vinyl-1,3-dioxane

$[\alpha]_D^{25} = +15.5$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (4R,5S)




2-[(2S,4R,5S)-5-Ethyl-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]-1-ethanol

$[\alpha]_D^{25} = +81.5$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (4R,5S)




2-[(2S,4R,5S)-5-Ethyl-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]acetic acid

$[\alpha]_D^{25} = +55.5$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (4R,5S)




Methyl 2-[(2S,4R,5S)-5-ethyl-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]acetate


$[\alpha]_D^{25} = +82.0$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (4*R*,5*S*)

 $C_7H_{12}O_3$   
(4*R*,5*S*)-5-Ethyl-4-hydroxytetrahydro-2*H*-2-pyranone


$[\alpha]_D^{22} = +22.9$  (*c* 1.1, CHCl<sub>3</sub>)  
Source of chirality: (S)-malic acid  
Absolute configuration: (4*R*,5*S*)

(2*R*,3*S*,4*S*)-4-Amino-2-tetradecyltetrahydro-3-furanol TFA salt

$[\alpha]_D^{25} = +13.6$  (*c* 1, EtOH)  
Chiral source: D-(-)-diethyl tartrate  
Absolute configuration: (2*R*,3*S*,4*S*)

tert-Pentyl N-(3*S*,4*S*,5*R*)-4-(benzyloxy)-5-[(*Z*)-2-tetradecenyl]tetrahydro-3-furanylcarbamate


$[\alpha]_D^{25} = +6.8$  (*c* 1, CHCl<sub>3</sub>)  
Chiral source: D-(-)-diethyl tartrate  
Absolute configuration: (3*S*,4*S*,5*R*)



C<sub>20</sub>H<sub>29</sub>NO<sub>6</sub>

Ethyl 2-((2*R*,3*S*,4*S*)-3-(benzyloxy)-4-[(tert-pentyloxy)carbonyl]aminotetrahydro-2-furanyl)acetate


$[\alpha]_D^{25} = +11.5$  (c 1, CHCl<sub>3</sub>)  
Chiral source: D-(-)-diethyl tartrate  
Absolute configuration: (2*R*,3*S*,4*S*)



C<sub>23</sub>H<sub>33</sub>NO<sub>6</sub>

tert-Butyl (4*S*)-4-[(1*R*,2*E*)-1-(benzyloxy)-4-ethoxy-4-oxo-2-butenyl]-2,2-dimethyl-1,3-oxazolane-3-carboxylate


$[\alpha]_D^{25} = -22.2$  (c 1, CHCl<sub>3</sub>)  
Chiral source: D-(-)-diethyl tartrate  
Absolute configuration: (4*S*,1*R*,2*E*)



C<sub>19</sub>H<sub>29</sub>NO<sub>5</sub>

tert-Butyl (4*S*)-4-[(1*S*)-1-benzyloxyethyl]-2,2 dimethyl-1,3-oxazolane-3-carbamate


$[\alpha]_D^{25} = -50.0$  (c 1, CHCl<sub>3</sub>)  
Chiral source: D-(-)-diethyl tartrate  
Absolute configuration: (1*R*,4*S*)



C<sub>15</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>


1-[(1*R*,2*S*)-2-(Benzylxy)-3-ethoxy-1-(ethoxycarbonyl)-3-oxopropyl]-1,2-triazadien-2-ium

$[\alpha]_D^{25} = +5.5$  (c 1, CHCl<sub>3</sub>)  
Chiral source: D-(-)-diethyl tartrate  
Absolute configuration: (1*R*,2*S*)




$[\alpha]_D^{25} = -30.5$  (*c* 1, CHCl<sub>3</sub>)  
Chiral source: D-(–)-diethyl tartrate  
Absolute configuration: (1*R*,2*S*)

1-[(1*R*,2*S*)-3-Ethoxy-1-(ethoxycarbonyl)-2-hydroxy-3-oxopropyl]-1,2-triazadien-2-ium




$[\alpha]_D^{25} = -45.4$  (*c* 1, CHCl<sub>3</sub>)  
Chiral source =D-(–)-Diethyl tartrate  
Absolute configuration = (1*S*,2*S*)

tert-butyl N-[(1*S*,2*S*)-2-(benzyloxy)-3-hydroxy-1-(hydroxymethyl)propyl]carbamate



$[\alpha]_D = -71.5$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: chiral auxiliary  
Absolute configuration: (2*S*,3*S*)


(2*R*)-N-[2*S*,3*S*)-2,4-Dimethyl-3-hydroxypentan-1-oyl]bornane-10,2-sultam




$[\alpha]_D = +8.0$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: chiral auxiliary  
Absolute configuration: (2*R*,3*S*)

(2*R*,3*S*)-2,4-Dimethylpentane-1,3-diol


$[\alpha]_D = +21.0$  (*c* 0.1, CHCl<sub>3</sub>)  
 Source of chirality: chiral auxiliary  
 Absolute configuration: (2*R*,3*S*)

(2*R*,3*S*)-3-Hydroxy-2,4-dimethylpentyl 4-methylbenzenesulfonate


$[\alpha]_D = -32.5$  (*c* 0.2, CHCl<sub>3</sub>)  
 Source of chirality: chiral auxiliary  
 Absolute configuration: (2*S*,3*S*)


(2*S*,3*S*)-1-Iodo-2,4-dimethylpentan-3-ol

$[\alpha]_D = -7.0$  (*c* 0.1, CHCl<sub>3</sub>)  
 Source of chirality: chiral auxiliary  
 Absolute configuration: (2*S*,3*S*)


(2*S*,3*S*)-1-Iodo-2,4-dimethylpentan-3-yl propionate

$[\alpha]_D = -24.5$  (*c* 0.1, CHCl<sub>3</sub>)  
 Source of chirality: chiral auxiliary  
 Absolute configuration: (3*S*,5*R*,6*S*)

4-{(3*S*)-4-[(4*S*,6*R*)-2,2-Dimethyl-6-tridecyl1,3-dioxan-4-yl]-3-hydroxybutyl}phenol

 $C_{20}H_{16}N_2O_6$ (S)- $\alpha$ -(Benzylxycarbonylaminophthamilido)- $\gamma$ -butyrolactone


$[\alpha]_D^{22} = -2.63$  (*c* 0.760, EtOH)  
Source of chirality: (*R*)- $\alpha$ -hydroxy- $\gamma$ -butyrolactone  
Absolute configuration: (S)

 $C_{22}H_{30}N_2O_8$ (S)- $\alpha$ -[ $N^{\alpha}$ -(Benzylxycarbonyl)- $N^{\beta},N^{\beta}$ -bis(*tert*-butyloxycarbonyl)hydrazino]- $\gamma$ -butyrolactone

$[\alpha]_D^{22} = -2.54$  (*c* 1.180, EtOH)  
Source of chirality: (*R*)- $\alpha$ -hydroxy- $\gamma$ -butyrolactone  
Absolute configuration: (S)

 $C_{17}H_{22}N_2O_6$ (S)- $\alpha$ -[ $N^{\alpha}$ -(Benzylxycarbonyl)- $N^{\beta}$ -(*tert*-butyloxycarbonyl)-hydrazino]- $\gamma$ -butyrolactone


$[\alpha]_D^{22} = -2.86$  (*c* 1.050, EtOH)  
Source of chirality: (*R*)- $\alpha$ -hydroxy- $\gamma$ -butyrolactone  
Absolute configuration: (S)

 $C_{20}H_{30}N_2O_7$ Isopropyl (2*S*)-2-[ $N^{\alpha}$ -(benzyloxycarbonyl)- $N^{\beta}$ -(*tert*-butyloxycarbonyl)hydrazino]-4-hydroxybutanoate

$[\alpha]_D^{22} = -0.74$  (*c* 1.360, EtOH)  
Source of chirality: (*R*)- $\alpha$ -hydroxy- $\gamma$ -butyrolactone  
Absolute configuration: (2*S*)

$[\alpha]_D^{22} = -12.94$  (*c* 0.850, EtOH)Source of chirality: (R)- $\alpha$ -hydroxy- $\gamma$ -butyrolactone

Absolute configuration: (3S)


 $C_{20}H_{28}N_2O_6$ 

Isopropyl (3S)-3-[2-(benzyloxycarbonyl)-(tert-butyl-oxy carbonyl)]pyrazolidine]-carboxylate

 $[\alpha]_D^{20} = +129.4$  (*c* 0.06,  $CH_3CH_2OH$ )


Source of chirality: 2-deoxy-D-ribose; enzymatic alcoholysis

Absolute configuration: (1S,3S,4R)

 $C_8H_{14}O_5$ (1S,3S,4R)-Methyl 3-O-acetyl-2-deoxy- $\alpha$ -D-ribofuranoside $[\alpha]_D^{20} = +89.4$  (*c* 0.04,  $CH_3CH_2OH$ )


Source of chirality: 2-deoxy-D-ribose; enzymatic alcoholysis


Absolute configuration: (1R,3S,4R)

 $C_9H_{14}O_6$ (1R,3S,4R)-1,3-Di-O-acetyl-2-deoxy- $\alpha$ -D-ribofuranose $[\alpha]_D^{20} = -13.3$  (*c* 0.12,  $CH_3CH_2OH$ )

Source of chirality: D-arabinose; enzymatic alcoholysis


Absolute configuration: (1R,2S,3R,4R)

 $C_{11}H_{16}O_8$ (1R,2S,3R,4R)-1,2,3-Tri-O-acetyl- $\alpha$ -D-arabinofuranose




$[\alpha]_D^{20} = -8$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-glucose  
Absolute configuration: (1S,2R,3S,4R,5R)

C<sub>37</sub>H<sub>39</sub>NO<sub>10</sub>S  
(5S,7R,8R,9S,10R)-8,9,10-Tribenzyloxy-7-benzyloxy)methyl-1-methoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide




$[\alpha]_D^{20} = +30$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-glucose  
Absolute configuration: (5S,7R,8R,9S,10R)

C<sub>40</sub>H<sub>45</sub>NO<sub>10</sub>S  
(5S,7R,8R,9S,10R)-8,9,10-Tribenzyloxy-7-benzyloxymethyl-1-tertbutyloxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide




$[\alpha]_D^{20} = +19$  (*c* 0.1, MeOH)  
Source of chirality: D-glucose  
Absolute configuration: (5S,7R,8R,9S,10R)

C<sub>9</sub>H<sub>15</sub>NO<sub>10</sub>S  
(5S,7R,8R,9S,10R)-8,9,10-Trihydroxy-7-hydroxymethyl-1-methoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide




$[\alpha]_D^{20} = -18$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-glucose  
Absolute configuration: (5S,7R,8R,9S,10S)


C<sub>35</sub>H<sub>37</sub>NO<sub>8</sub>S  
(5S,7R,8R,9S,10R)-8,9,10-Tribenzyloxy-7-benzyloxymethyl-1-amino-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide




$[\alpha]_D^{20} = +36$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-mannose  
Absolute configuration: (5S,7R,8R,9S,10S)




(5S,7R,8R,9S,10S)-8,9,10-Tribenzyloxy-7-benzyloxymethyl-1-methoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide




$[\alpha]_D^{20} = +26$  (*c* 0.1, MeOH)  
Source of chirality: D-glucose  
Absolute configuration: (5S,7R,8R,9S,10R)




(5S,7R,8R,9S,10R)-8,9,10-Trihydroxy-7-hydroxymethyl-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide




$[\alpha]_D^{20} = +12$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-mannose  
Absolute configuration: (5R,7R,8R,9S,10S)




(5R,7R,8R,9S,10S)-8,9,10-Tribenzyloxy-7-benzyloxymethyl-1-methoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.5]decan-2,2-dioxide



$[\alpha]_D^{20} = -28$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-ribose  
Absolute configuration: (5S,7R,8S,9S)




(5S,7R,8S,9S)-8,9-Dimethylmethylenedioxy-7-*tert*-butyldiphenylsilyloxymethyl-1-methoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.4]nonan-2,2-dioxide




$[\alpha]_D^{20} = -56$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-ribose  
Absolute configuration: (5*R*,7*R*,8*S*,9*S*)

(5*R*,7*R*,8*S*,9*S*)-8,9-Dimethylmethylenedioxy-7-*tert*-butyldiphenylsilyloxymethyl-1-methoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.4]nonan-2,2-dioxide




$[\alpha]_D^{20} = +12$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-arabinose  
Absolute configuration: (5*R*,7*R*,8*S*,9*R*)

(5*R*,7*R*,8*S*,9*R*)-8,9-Dibenzylxyloxy-7-benzyloxymethyl-1-*tert*butoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.4]nonan-2,2-dioxide




$[\alpha]_D^{20} = +36$  (*c* 0.1, CHCl<sub>3</sub>)  
Source of chirality: D-arabinose  
Absolute configuration: (5*S*,7*R*,8*S*,9*R*)

(5*S*,7*R*,8*S*,9*R*)-8,9-Dibenzylxyloxy-7-benzyloxymethyl-1-*tert*butoxycarbonyl-3,6-dioxa-2-thia-1-azaspiro[4.4]nonan-2,2-dioxide



Ee >98%  
 $[\alpha]_D = -218.4$  (*c* 1.19, CHCl<sub>3</sub>)  
Source of chirality: (S)-phenylethylamine  
Absolute configuration: 3*S*,4*R*,1*S*

(3*S*,4*R*,1*S*)-3-Benzylideneamino-4-*t*-butyldimethylsilyloxymethyl-1-(1'-phenylethyl)pyrrolidin-2-one




Ee >98%

$[\alpha]_D = -230.7$  (c 1.04, CHCl<sub>3</sub>)

Source of chirality: (S)-4-methoxyphenylethylamine

Absolute configuration: 3S,4R,1'S

C<sub>27</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub>Si  
(3S,4R,1'S)-3-Benzylideneamino-4-[(t-butyldimethylsilyloxy)methyl]-1-[1'-(4-methoxyphenyl)ethyl]pyrrolidin-2-one




Ee >98%

$[\alpha]_D = -6.7$  (c 0.74, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3R,4R,1'S

C<sub>27</sub>H<sub>38</sub>N<sub>2</sub>O<sub>2</sub>Si  
(3R,4R,1'S)-3-Benzylideneamino-4-t-butyldimethylsilyloxymethyl-3-methyl-1-(1'-phenylethyl)pyrrolidin-2-one




Ee >98%

$[\alpha]_D = -17.5$  (c 1.14, CHCl<sub>3</sub>)

Source of chirality: (S)-4-methoxyphenylethylamine

Absolute configuration: 3R,4R,1'S

C<sub>28</sub>H<sub>40</sub>N<sub>2</sub>O<sub>3</sub>Si  
(3R,4R,1'S)-3-Benzylideneamino-4-t-butyldimethylsilyloxymethyl-1-[1'-(4-methoxyphenyl)ethyl]-3-methylpyrrolidin-2-one




Ee >98%

$[\alpha]_D = -22.7$  (c 1.25, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine


Absolute configuration: 3R,4R,1'S

C<sub>33</sub>H<sub>42</sub>N<sub>2</sub>O<sub>2</sub>Si  
(3R,4R,1'S)-3-Benzyl-3-benzylideneamino-4-t-butyldimethylsilyloxymethyl-1-(1'-phenylethyl)pyrrolidin-2-one




C<sub>29</sub>H<sub>40</sub>N<sub>2</sub>O<sub>2</sub>Si  
(3R,4R,1'S)-3-Allyl-3-benzylideneamino-4-t-butyldimethylsilyloxymethyl-1-(1'-phenylethyl)pyrrolidin-2-one

Ee >98%  
[ $\alpha$ ]<sub>D</sub> = -31.7 (c 1.5, CHCl<sub>3</sub>)  
Source of chirality: (S)-phenylethylamine  
Absolute configuration: 3R,4R,1'S




C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>  
(3R,4R,1'S)-3-Amino-4-hydroxymethyl-1-[1'-(4-methoxyphenyl)ethyl]-3-methylpyrrolidin-2-one

Ee >98%  
[ $\alpha$ ]<sub>D</sub> = -110.0 (c 0.54, CHCl<sub>3</sub>)  
Source of chirality: (S)-4-methoxyphenylethylamine  
Absolute configuration: 3R,4R,1'S





C<sub>16</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>  
(4aR,7aR,1'S)-6-[1'-(4-Methoxyphenyl)ethyl]-7a-methylhexahydropyrrolo[3,4-d][1,3]oxazine-2,7-dione

Ee >98%  
[ $\alpha$ ]<sub>D</sub> = -108.2 (c 1.04, CHCl<sub>3</sub>)  
Source of chirality: (S)-4-methoxyphenylethylamine  
Absolute configuration: 4aR,7aR,1'S



C<sub>20</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>  
(3R,4R,1'S)-3-t-Butoxycarbonylamino-4-hydroxymethyl-1-[1'-(4-methoxyphenyl)ethyl]-3-methylpyrrolidin-2-one

Ee >98%  
[ $\alpha$ ]<sub>D</sub> = -125.0 (c 1.16, CHCl<sub>3</sub>)  
Source of chirality: (S)-4-methoxyphenylethylamine  
Absolute configuration: 3R,4R,1'S





(3R,4R)-3-t-Butoxycarbonylamino-4-hydroxymethyl-3-methylpyrrolidin-2-one

Ee >98%

[α]<sub>D</sub> = -50.0 (c 0.6, CHCl<sub>3</sub>)

Source of chirality: (S)-4-methoxyphenylethylamine

Absolute configuration: 3R,4R





(3R,4R,1'S)-Methyl 4-t-butoxycarbonylamino-1-[1'-(4-methoxyphenyl)ethyl]-4-methyl-5-oxopyrrolidine-3-carboxylate

Ee >98%

[α]<sub>D</sub> = -104.5 (c 1.32, CHCl<sub>3</sub>)

Source of chirality: (S)-4-methoxyphenylethylamine

Absolute configuration: 3R,4R,1'S





(3R,4R)-Methyl 4-t-butoxycarbonylamino-4-methyl-5-oxopyrrolidine-3-carboxylate

Ee >98%

[α]<sub>D</sub> = -43.8 (c 0.57, CHCl<sub>3</sub>)

Source of chirality: (S)-4-methoxyphenylethylamine

Absolute configuration: 3R,4R



(2R,3'S)-3,3,3-Trifluoro-2-methoxy-2-phenylpropionic acid 3'-hydroxy-2'-oxo-pentyl ester

De = 55% [(2R,3'S)-major isomer, (2R,3'R) present]

[α]<sub>D</sub><sup>20</sup> = +13.3 (c 0.15, CHCl<sub>3</sub>)

Source of chirality: biocatalysis



Absolute configuration: (2R,3'S)

De = 55% [(2S,3'S)-major isomer, (2S,3'R) present]

 $[\alpha]_D^{20} = -37.0$  (*c* 0.1, CHCl<sub>3</sub>)

Source of chirality: biocatalysis

Absolute configuration: (2S,3'S)




(2S,3'S) 3,3,3-Trifluoro-2-methoxy-2-phenylpropionic acid 3'-hydroxy-2'-oxo-pentyl ester

De = &gt;95% (2R,3'S)

 $[\alpha]_D^{20} = +10.2$  (*c* 0.4, CHCl<sub>3</sub>)

Source of chirality: biocatalysis

Absolute configuration: (2R,3'S)




(2R,3'S) 3,3,3-Trifluoro-2-methoxy-2-phenylpropionic acid 3',4'-dihydroxy-2'-oxo-butyl ester

De = &gt;95% (2S,3'S)

 $[\alpha]_D^{20} = -14.4$  (*c* 0.5, CHCl<sub>3</sub>)

Source of chirality: biocatalysis

Absolute configuration: (2S,3'S)





(2S,3'S) 3,3,3-Trifluoro-2-methoxy-2-phenylpropionic acid 3',4'-dihydroxy-2'-oxo-butyl ester

De = 57% [(2R,3'S)-major isomer, (2R,3'R) present]

 $[\alpha]_D^{20} = +23.2$  (*c* 0.25, CHCl<sub>3</sub>)

Source of chirality: biocatalysis

Absolute configuration: (2R,3'S)




(2R,3'S) 3,3,3-Trifluoro-2-methoxy-2-phenylpropionic acid 3'-hydroxy-4'-methoxy-2'-oxo-butyl ester

De = 57% [(2S,3'S)-major isomer, (2S,3'R) present]

 $[\alpha]_D^{20} = -10.6$  (*c* 0.25, CHCl<sub>3</sub>)

Source of chirality: biocatalysis

Absolute configuration: (2S,3'S)

 $C_{15}H_{17}F_3O_6$ 


(2S,3'S)-3,3,3-Trifluoro-2-methoxy-2-phenylpropionic acid 3'-hydroxy-4'-methoxy-2'-oxo-butyl ester

Ee = 57% [(3S)-major isomer]

 $[\alpha]_D^{20} = +2.0$  (*c* 2.0, CHCl<sub>3</sub>)

Source of chirality: biocatalysis

Absolute configuration: (3S)

 $C_5H_{10}O_4$ 

(3S)-1,3-Dihydroxy-4-methoxybutan-2-one